Fishawack Health appoints life science industry guru, Deborah Keller as its new Chair

04 March 2021

Fishawack Health welcomes Deborah Keller as the new chair of its board, helping to drive its next phase of growth.

We’re delighted to announce the appointment of Deborah Keller as the new chair of our Board. Deborah’s appointment signals the next phase in our robust growth strategy designed to continuously build our team of the best-of-the-best clinical and commercial experts, delivering cutting-edge end-to-end solutions for our clients across the product lifecycle.

With more than 3 decades of experience, she brings exceptional leadership from a career supporting and scaling fast-growing, people-based businesses in healthcare, including her role as the CEO of Covance where she led a team of over 13,000 employees in 60 countries and was responsible for more than $2.6 billion in business.

Deborah has dedicated her life to improving patient outcomes and uncovering innovative ways to bring value to the pharmaceutical industry. She will bring unique knowledge and innovative thinking that will empower stakeholders to shape and affect connections between people and life-enhancing therapies. Her counsel will also be invaluable for leading Fishawack Health to consolidate its integration, scale its client value proposition and global infrastructure.

Deborah Keller, Fishawack Health Chair

Deborah adds, “The team’s exceptional expertise stood out to me. As someone who worked at the same company over a long period and eventually led the leadership team, I know how important it is to allow every employee to develop, grow and thrive. Doing so will ensure we better deliver for our clients, patients, and healthcare professionals.”

Deborah’s appointment follows the recent acquisitions of The Hive Health Group and StoneArch. We are now powered by a 950+ and growing, globe-spanning pack of strategic, creative, and scientific experts, operating across 17 offices in 13 cities in the US and UK, with combined revenue of more than $150 million.

Read the full press release on PharmaLive.


Latest articles

Mum’s the word: why we’re supporting working mothers

10 May 2021

Deep 6 AI: the smart software breathing new life into clinical trials

05 May 2021

UK vs US: what makes a successful immunization program?

29 April 2021

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.